問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taichung Veterans General Hospital (在職)

Division of Rheumatology

China Medical University Hospital (在職)

Division of Rheumatology

Division of General Internal Medicine

更新時間：2023-09-19

陳得源Der-Yuan, Chen
  • Principal Investigator
  • Clinical Trial Experience (year)

  • 095959@tool.caaumed.org.tw

Recruiting Trial

16Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳得源

List

64Cases

2011-02-01 - 2017-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

2016-11-13 - 2021-12-13

Phase III

A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 Weeks Alone and in Combination with Methotrexate (MTX) to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Are Naïve to MTX Therapy

  • Condition/Disease

    Rheumatoid Arthritis

  • Test Drug

    Filgotinib

Participate Sites
9Sites

Terminated9Sites

2012-08-01 - 2016-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2015-07-01 - 2019-10-29

Phase III

A Multicenter, Randomized, Double-Blind, Placebo-Controlled 24-Week Study Followed by Long-Term Evaluation of Efficacy and Safety of Ixekizumab (LY2439821) in Biologic Disease-Modifying Antirheumatic Drug- Experienced Patients with Active Psoriatic Arthritis

  • Condition/Disease

    Active Psoriatic Arthritis

  • Test Drug

    Ixekizumab(LY2439821)

Participate Sites
8Sites

Terminated7Sites

黃毓惠
Linkou Chang Gung Medical Foundation

Division of Dermatology

藍忠亮
China Medical University Hospital-Taipei

未分科

2008-08-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2008-07-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2011-10-01 - 2012-11-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2015-10-05 - 2015-10-05

Phase II

A Multicentre, Randomised, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Efficacy and Safety of Anifrolumab in Adult Subjects with Active Proliferative Lupus Nephritis

  • Condition/Disease

    Active Proliferative Lupus Nephritis

  • Test Drug

    Anifrolumab

Participate Sites
6Sites

Terminated6Sites

2011-01-01 - 2019-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-04-01 - 2019-03-19

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Terminated7Sites

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB